Atai Life Sciences Nv (ATAI)

$1.59

+0.01

(+0.63%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.58
    $1.64
    $1.59
    downward going graph

    0.63%

    Downside

    Day's Volatility :3.66%

    Upside

    3.05%

    downward going graph
  • $1.02
    $2.85
    $1.59
    downward going graph

    35.85%

    Downside

    52 Weeks Volatility :64.21%

    Upside

    44.21%

    downward going graph

Returns

PeriodAtai Life Sciences NvSector (Health Care)Index (Russel 2000)
3 Months
-18.13%
6.5%
0.0%
6 Months
-8.14%
7.1%
0.0%
1 Year
-23.3%
9.8%
0.0%
3 Years
-90.28%
14.2%
-20.2%

Highlights

Market Capitalization
262.8M
Book Value
$1.34
Earnings Per Share (EPS)
-0.21
Wall Street Target Price
10.68
Profit Margin
0.0%
Operating Margin TTM
-41314.8%
Return On Assets TTM
-26.02%
Return On Equity TTM
-15.92%
Revenue TTM
277.0K
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-52.6%
Gross Profit TTM
233.0K
EBITDA
-114.1M
Diluted Eps TTM
-0.21
Quarterly Earnings Growth YOY
-0.97
EPS Estimate Current Year
-0.64
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.18
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Atai Life Sciences Nv(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
11
12
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 571.7%

Current $1.59
Target $10.68

Technicals Summary

Sell

Neutral

Buy

Atai Life Sciences Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Atai Life Sciences Nv
Atai Life Sciences Nv
21.54%
-8.14%
-23.3%
-90.28%
-91.88%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Atai Life Sciences Nv
Atai Life Sciences Nv
NA
NA
NA
-0.64
-0.16
-0.26
NA
1.34
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Atai Life Sciences Nv
Atai Life Sciences Nv
Buy
$262.8M
-91.88%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Atai Life Sciences Nv

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 172.0K → 18.0K (in $), with an average decrease of 64.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 44.24M → -26.71M (in $), with an average decrease of 93.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 84.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 276.8%

Institutional Holdings

  • Morgan Stanley - Brokerage Accounts

    1.59%

  • Millennium Management LLC

    1.32%

  • BlackRock Inc

    0.84%

  • Marshall Wace Asset Management Ltd

    0.47%

  • Brown University

    0.43%

  • Vanguard Group Inc

    0.25%

Company Information

who we are: atai is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. our mission: we are committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. our approach: by pooling expertise, best practices, and resources across our entire portfolio, we mitigate risk and responsibly accelerate the development of impactful and evidence-based treatments.

Organization
Atai Life Sciences Nv
Employees
83
CEO
Mr. Christian Angermayer
Industry
Commercial Services

Discover More

FAQs